NPM
Asset Logo

Newpeak Metals Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

โ›๏ธ MINING

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

+ 60.00%
Annual Growth

5 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

1
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

NewPeak Metals Ltd. engages in coal and lithium exploration in Argentina, oil and gas in Australia, and gold exploration in U.S. Its projects include cachi gold, san Jorge lithium brine and las openas gold. The company is headquartered in Brisbane, Queensland. The company went IPO on 2011-04-11. The firm has gold exploration assets in three of the mining jurisdictions globally: Finland, Argentina and New Zealand. The company has a suite of gold projects in a region in Finland which hosts three gold mines, Orivesi, Jokisivu and Kaapelinkulma. The Las Openas Gold Project is located in the province of San Juan, with a lease area of approximately 1,462 hectares. The Cachi Gold Project is a Caldera hosted epithermal gold vein system spanning approximately 10 kilometers across and five kilometers in width. The company owns a 75% stake in the Cap Burn Gold Project, in Otago, New Zealand, through an earn-in joint venture with Mineral Rangahau Joint Venture. The company has 100% ownership in several other gold properties, between OceanaGoldโ€™s Macraes Mine in the east, and the Santana-Matakanui Bendigo-Ophir project in the west. The company also has a group of mineral and tungsten exploration assets in Sweden.

๐Ÿ“ˆ Performance

Price History

+140.00%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.01

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in NPM

1

๐Ÿ“Š Total Capital Earnings

$4K

๐Ÿ”ƒ Average investment frequency

10 weeks

๐Ÿ’ต Average investment amount

$2,032

โฐ Last time a customer invested in NPM

84 days
NPM investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

100%

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

100%
๐Ÿ™‹ Legal gender of investors

Female

100%

Male

Pearlers who invest in NPM also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

3.85%

๐Ÿ“Š Share price

$100.90 AUD

โ›ณ๏ธ DIVERSIFIED

๐Ÿ‡ฆ๐Ÿ‡บ AUSTRALIA

๐Ÿงฑ MATERIALS

๐Ÿ’ธ FINANCIALS

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

12.86%

๐Ÿ“Š Share price

$129.54 AUD

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

๐Ÿค– TECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 153.93m in AUM and 205 holdings. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index).

๐Ÿ™Œ Performance (5Yr p.a)

5.37%

๐Ÿ“Š Share price

$25.09 AUD

๐Ÿค– TECHNOLOGY

๐Ÿ‡ฆ๐Ÿ‡บ EX AUSTRALIA

VGE.AX was created on 2013-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Seeks to track the return of the FTSE Emerging Markets All Cap China A Inclusion Index in Australian dollars, before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

2.80%

๐Ÿ“Š Share price

$78.78 AUD

โ›ณ๏ธ DIVERSIFIED

๐ŸŒ GLOBAL

IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks

๐Ÿ™Œ Performance (5Yr p.a)

10.20%

๐Ÿ“Š Share price

$140.56 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿ‡บ๐Ÿ‡ธ UNITED STATES

Want more shares? Try these...

๐Ÿ“Š Share price

$0.01 AUD

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales and currently employs 1,000 full-time employees. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

๐Ÿ™Œ Performance (5Yr p.a)

-14.20%

๐Ÿ“Š Share price

$0.10 AUD

๐Ÿงฌ BIOTECHNOLOGY

Compare
Add to watchlist